Cyllene Therapeutics raises €33 million Series C and rebrands from EG 427

The financing, co-led by GordonMD Global Investments and M Ventures, will fund later-stage development of EG110A and expansion of the company’s HERMES nrHSV-1 platform in neurology.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.